Samuel N. Hazen - 18 Feb 2022 Form 4 Insider Report for HCA Healthcare, Inc. (HCA)

Role
CEO, Director
Signature
/s/ Natalie Harrison Cline, Attorney-in-Fact
Issuer symbol
HCA
Transactions as of
18 Feb 2022
Net transactions value
-$8,746,103
Form type
4
Filing time
23 Feb 2022, 18:16:58 UTC
Previous filing
01 Feb 2022
Next filing
01 Feb 2023
SEC
View on sec.gov

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction HCA Common Stock Award $0 +85,040 +26% $0.000000 408,704 18 Feb 2022 Direct F1
transaction HCA Common Stock Options Exercise +6,011 +1.5% 414,715 18 Feb 2022 Direct F2
transaction HCA Common Stock Tax liability $8,746,103 -35,830 -8.6% $244.10 378,885 18 Feb 2022 Direct
holding HCA Common Stock 813,320 18 Feb 2022 By LP

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction HCA Restricted Stock Units Options Exercise $0 -6,011 -100% $0.000000* 0 18 Feb 2022 Common Stock 6,011 Direct F2
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 On January 30, 2019, the reporting person was granted 42,520 performance share units. The performance share units were eligible to vest based on achievement of a cumulative earnings per share goal for fiscal years 2019-2021. The number of performance share units that were eligible to vest varied from zero (for actual performance less than 90% of target) to two times the units granted (for actual performance of 110% or more of target). Based upon the Company's achievement with respect to cumulative 2019-2021 earnings per share, the number of performance share units that vested equaled 200% of the units granted.
F2 Restricted stock units convert into common stock on a one-for-one basis.